Poster 1658: CD137 Target Humanized Model Established

Establishment of a CD137 Humanized Mouse Model for Efficacy Assessment of Agonistic Anti-CD137 Therapeutic Antibodies

Davy Xuesong Ouyang, Gang Chen*, Zhun Wang, Lei Zheng, Zhensheng Wang, Lei Liu, Annie Xiaoyu An, Jean-Pierre Wery, Jay Liu*, Xin Dong*, and Henry Q. Li

*Nanjing Galaxy Biopharmaceutical Co. Ltd., Nanjing, China

CD137 belongs to the TNF receptor super family, and its activation is essential to the function of T cells and NK cells.

Multiple agonistic CD137 antibodies are currently being tested for advanced cancer, and are expected to become important new clinical immunotherapeutics.

Preclinical models are essential for the efficacy assessment of investigational CD137 antibodies before entering the clinic; however, currently available immunocompetent animal models cannot meet this need e.g. syngeneics due to species specificity issues.

Read this Poster to Discover:

• The creation of a human CD137 knock-in model expressing chimeric human/mouse CD137, composed of human extracellular and transmembrane domains (exons 4-7), with intact mouse signal peptide and intracellular domains
  
  
• Humanized model validation including chimeric CD137 expression levels and reactivity to human CD137 antibodies
  
  
• A range of preclinical target humanized models, including PD-1, CTLA-4, and CD137, used to assess immuno-oncology mAb therapeutic efficacy

Download the Poster Now!